Semler Scientific Inc. has announced a new liquidity contract through a Controlled Equity Offering Sales Agreement with a consortium of financial institutions including Barclays Capital Inc., Cantor Fitzgerald & Co., Canaccord Genuity LLC, Needham & Company, LLC, Craig-Hallum Capital Group LLC, and Lake Street Capital Markets, LLC. The agreement allows for the issuance and sale of up to $500 million in common stock through an at-the-market $(ATM.UK)$ offering program. As of early June 2025, the company has already issued and sold over 3.5 million shares, generating net proceeds of approximately $136.2 million. This move is set to enhance liquidity and provide additional financial flexibility.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。